IGF-1 LR3 Receptor Grade is a modified form of Insulin-Like Growth Factor-1 engineered for enhanced stability and biological activity. Commonly used in research to support cellular growth, tissue repair, and regeneration, it can be paired with Ipamorelin or NAD+ for synergistic effects.
$93.00
For laboratory research use only. Not for human or animal use or consumption. Not a drug, food, dietary supplement, or cosmetic. Not approved by the FDA for any medical use.
IGF-1 LR3 (Long Arg3 Insulin-like Growth Factor-1) is a recombinant peptide analogue of human IGF-1 designed for enhanced stability, extended half-life, and increased bioavailability. Modifications including arginine substitution at position 3 and removal of the N-terminal glutamic acid reduce binding to IGF-binding proteins (IGFBPs), allowing a half-life of 20–30 hours compared to 20–30 minutes for native IGF-1.
Acts downstream of Growth Hormone (GH) to promote cellular growth, differentiation, and repair
Stimulates muscle, cartilage, and connective tissue regeneration
Enhances tissue remodeling, cellular repair, and recovery
When stacked with Ipamorelin, can amplify GH-mediated effects
Research shows NAD+ co-administration may increase energy and exercise performance
Typical Dose: 50–100 mcg administered in the morning, fasted, before workouts
Cycle Length: 10–20 consecutive days, followed by an off-cycle of 4–8 weeks
Carbohydrates and fats may blunt GH-related effects; best administered 30 minutes before meals or 2 hours after eating
Increased hunger (can be beneficial depending on protocol)
Water retention
Tingling in extremities
Gradual dose escalation is recommended to minimize side effects
Class: Recombinant Insulin-like Growth Factor-1 analogue
Category: Growth Hormone Peptides
Primary Research Focus: Cellular growth, tissue repair, regeneration, and recovery
Reviews
There are no reviews yet.